← Eichor
Condition: Gep Neuroendocrine Tumor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Gep Neuroendocrine Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancr
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05884255Protocol ITANET - Registry
Phase N/A · 37 location(s) · Italian Association Neuroendocrine Tumors · NCT04282083Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07302100Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT05196087Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Phase 4 · 19 location(s) · University Hospital, Antwerp · NCT05701241A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06505395Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
NA · 2 location(s) · Nantes University Hospital · NCT06735560Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionucl
NA · 5 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06256705Spanish Series of Patients Treated With the Radionuclide Lutetium177
Phase N/A · 20 location(s) · Sociedad Española de Medicina Nuclear e Imagen Molecular · NCT04949282Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Phase 1 · 9 location(s) · RayzeBio, Inc. · NCT07165132Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT0642779868Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06155318Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06356467Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3 · 65 location(s) · Novartis Pharmaceuticals · NCT06784752Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for
Phase 1 · 1 location(s) · Stanford University · NCT04609592Life Following Excision of Neuroendocrine Tumors
Phase N/A · 1 location(s) · Sunnybrook Health Sciences Centre · NCT06981455Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroe
Phase 2 · 39 location(s) · National Cancer Institute (NCI) · NCT05773274Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric P
Phase 1 · 5 location(s) · ITM Solucin GmbH · NCT06441331A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Pro
Phase 2 · 1 location(s) · National Cancer Institute, Naples · NCT04893785Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Phase N/A · 2 location(s) · Methodist Health System · NCT04090034DCEUS to Assess Treatment Response to PRRT in GEP-NET
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07319416Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GE
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04086485Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Meta
Phase 2 · 4 location(s) · University Hospital, Bordeaux · NCT04837885Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Sol
Phase 1/Phase 2 · 5 location(s) · Molecular Partners AG · NCT07278479Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastr
Phase 2/Phase 3 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT07165886Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 17
Phase 3 · 54 location(s) · RayzeBio, Inc. · NCT05477576Observational Study on GEP-and Pulm-NET Treated at FPG
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06402695A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens
Phase 1 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06732505PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Phase 3 · 2 location(s) · Tata Memorial Hospital · NCT07185672
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.